These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 32460605)
21. Evaluation and Management of Hypoactive Sexual Desire Disorder. Clayton AH; Kingsberg SA; Goldstein I Sex Med; 2018 Jun; 6(2):59-74. PubMed ID: 29523488 [TBL] [Abstract][Full Text] [Related]
22. Flibanserin and its discontents. Aftab A; Chen C; McBride J Arch Womens Ment Health; 2017 Apr; 20(2):243-247. PubMed ID: 27858170 [TBL] [Abstract][Full Text] [Related]
23. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. Althof S; Derogatis LR; Greenberg S; Clayton AH; Jordan R; Lucas J; Spana C J Sex Med; 2019 Aug; 16(8):1226-1235. PubMed ID: 31277966 [TBL] [Abstract][Full Text] [Related]
24. Flibanserin for female sexual dysfunction. Reviriego C Drugs Today (Barc); 2014 Aug; 50(8):549-56. PubMed ID: 25187905 [TBL] [Abstract][Full Text] [Related]
25. New developments in the treatment of hypoactive sexual desire disorder - a focus on Flibanserin. Jayne CJ; Heard MJ; Zubair S; Johnson DL Int J Womens Health; 2017; 9():171-178. PubMed ID: 28442935 [TBL] [Abstract][Full Text] [Related]
26. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Parish SJ; Simon JA; Davis SR; Giraldi A; Goldstein I; Goldstein SW; Kim NN; Kingsberg SA; Morgentaler A; Nappi RE; Park K; Stuenkel CA; Traish AM; Vignozzi L J Sex Med; 2021 May; 18(5):849-867. PubMed ID: 33814355 [TBL] [Abstract][Full Text] [Related]
27. Characteristics of premenopausal and postmenopausal women with acquired, generalized hypoactive sexual desire disorder: the Hypoactive Sexual Desire Disorder Registry for women. Rosen RC; Maserejian NN; Connor MK; Krychman ML; Brown CS; Goldstein I Menopause; 2012 Apr; 19(4):396-405. PubMed ID: 22076307 [TBL] [Abstract][Full Text] [Related]
28. Medical Treatment of Female Sexual Dysfunction. Nappi RE; Tiranini L; Martini E; Bosoni D; Righi A; Cucinella L Urol Clin North Am; 2022 May; 49(2):299-307. PubMed ID: 35428435 [TBL] [Abstract][Full Text] [Related]
29. The presentation of hypoactive sexual desire disorder in premenopausal women. Maserejian NN; Shifren JL; Parish SJ; Braunstein GD; Gerstenberger EP; Rosen RC J Sex Med; 2010 Oct; 7(10):3439-48. PubMed ID: 20646184 [TBL] [Abstract][Full Text] [Related]
30. What Women Want? The State of the Art regarding the Treatment of Young Women with Hypoactive Sexual Desire Disorder. de Oliveira L; Vignozzi L; Giraldi A; Varod S; Corona G; Reisman Y Pharmacology; 2024; 109(2):69-75. PubMed ID: 38151009 [TBL] [Abstract][Full Text] [Related]
31. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Parish SJ; Simon JA; Davis SR; Giraldi A; Goldstein I; Goldstein SW; Kim NN; Kingsberg SA; Morgentaler A; Nappi RE; Park K; Stuenkel CA; Traish AM; Vignozzi L J Womens Health (Larchmt); 2021 Apr; 30(4):474-491. PubMed ID: 33797277 [No Abstract] [Full Text] [Related]
33. Instruments for Screening, Diagnosis, and Management of Patients with Generalized Acquired Hypoactive Sexual Desire Disorder. Derogatis LR; Revicki DA; Clayton AH J Womens Health (Larchmt); 2020 Jun; 29(6):806-814. PubMed ID: 32096691 [TBL] [Abstract][Full Text] [Related]
34. Aromatase Inhibitors Are Associated With Low Sexual Desire Causing Distress and Fecal Incontinence in Women: An Observational Study. Robinson PJ; Bell RJ; Christakis MK; Ivezic SR; Davis SR J Sex Med; 2017 Dec; 14(12):1566-1574. PubMed ID: 29066307 [TBL] [Abstract][Full Text] [Related]
35. Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). Clayton AH; Goldfischer ER; Goldstein I; Derogatis L; Lewis-D'Agostino DJ; Pyke R J Sex Med; 2009 Mar; 6(3):730-8. PubMed ID: 19170868 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis. Jaspers L; Feys F; Bramer WM; Franco OH; Leusink P; Laan ET JAMA Intern Med; 2016 Apr; 176(4):453-62. PubMed ID: 26927498 [TBL] [Abstract][Full Text] [Related]
37. Weight Loss in Women Taking Flibanserin for Hypoactive Sexual Desire Disorder (HSDD): Insights Into Potential Mechanisms. Simon JA; Kingsberg SA; Goldstein I; Kim NN; Hakim B; Millheiser L Sex Med Rev; 2019 Oct; 7(4):575-586. PubMed ID: 31196764 [TBL] [Abstract][Full Text] [Related]
38. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. Thorp J; Simon J; Dattani D; Taylor L; Kimura T; Garcia M; Lesko L; Pyke R; J Sex Med; 2012 Mar; 9(3):793-804. PubMed ID: 22239862 [TBL] [Abstract][Full Text] [Related]
39. Management of hypoactive sexual desire disorder in transgender women: a guide for clinicians. Cocchetti C; Ristori J; Mazzoli F; Vignozzi L; Maggi M; Fisher AD Int J Impot Res; 2020 Nov; 33(7):703-709. PubMed ID: 33558671 [TBL] [Abstract][Full Text] [Related]
40. Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women. Fabre LF; Brown CS; Smith LC; Derogatis LR J Sex Med; 2011 May; 8(5):1411-9. PubMed ID: 21324094 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]